The burden of dyslipidaemia in an urban Libyan population: Epidemiological assessment and a review of modern therapy

Abstract :

Dyslipidemia is a major modifiable risk factor for cardiovascular disease, yet data from Libyan populations remain limited. This study aims to investigate the prevalence, patterns, and demographic determinants of dyslipidemia among residents of Zawia City, Libya, and to provide a concise review of lipid-lowering therapies, including emerging ones. It is a cross-sectional study of 508 individuals of all ages and both sexes registered at many clinical laboratory centers across Zawia City for lipid profile testing from January 1, 2026, to May 31, 2026. Dyslipidemia was defined according to the National Cholesterol Education Program (NCEP) and ATPIII criteria. Statistical analysis was performed on all lipid parameters and expressed as mean ± SD, frequency, and percentage. The prevalence of all dyslipidemia patterns was assessed across age and gender groups. The findings showed that 81.6% of participants had at least one form of dyslipidemia. High LDL-C was the most common lipid abnormality (61.6%), followed by hypertriglyceridemia (36.2%), low HDL-C (36.0%), and hypercholesterolemia (27.8%). Clear gender differences were observed: Females had significantly higher rates of hypercholesterolemia (30.6%/24.3% for female/male, p < 0.05) and high LDL-C (65.1/57.4% for female/male, p < 0.01). By contrast, males exhibited significantly higher rates of low HDL-C (54.8/20.5% for male/female, p < 0.001). The high-risk ratio was twofold higher in males than in females (43.0/19.8% for male/female, p < 0.001). Age-specific analysis showed that all lipid abnormalities peaked in the 41–50-year age group, where the prevalence of hypercholesterolemia, hypertriglyceridemia, high LDL-C, and low HDL-C (36.4%, 45.7%,74.3%, and 44.3%, respectively) was greatest. These results demonstrate that dyslipidemia is highly prevalent among the population in Zawia City, with LDL-C abnormalities predominating and midlife individuals bearing the greatest burden. The presence of gender-specific patterns underscores the need for targeted prevention and control strategies. Routine screening and tailored interventions are urgently required to reduce cardiovascular disease risk in the Libyan population.

References

1. Gao H, Wang H, Shan G, Liu R, Chen H, Sun S, et al. Prevalence of dyslipidemia and associated risk factors among adult residents of Shenmu City, China. PLoS ONE. 2021; 16(5): e0250573. doi: 10.1371/journal.pone. 0250573
2. Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology. 2007; 132(6): 2181-2190. doi: 10.1053/j.gastro.2007.03.056
3. World Health Organization. The global health observatory. Available from: https://www.who.int/data/gho/ indicator-metadata-registry/imr-details /3236
4. Mattiuzzi C, Sanchis-Gomar F, Lippi G. Worldwide Burden of LDL Cholesterol: Implications in cardiovascular disease. Nutrition, Metabolism, and Cardiovascular Diseases. 2020; 30(2): 241-242. doi: 10.1016/j.numecd. 2019.09.008
5. Ghazwani M, Mahmood SE, Gosadi IM, Bahri AA, Ghazwani SH, Khmees RA. Prevalence of dyslipidemia and its determinants among the adult population of the Jazan Region. International Journal of General Medicine. 2023; 16: 4215-4226. doi: 10.2147/IJGM.S429462
6. Abera A, Worede A, Hirigo AT, Alemayehu R, Ambachew S. Dyslipidemia and associated factors among adult cardiac patients: A hospital-based comparative cross-sectional study. European Journal of Medical Research. 2024; 29(1): 237. doi: 10.1186/s40001-024-01802-x
7. Dybiec J, Baran W, Dąbek B, Fularski P, Młynarska E, Radzioch E, et al. Advances in treatment of dyslipidemia. International Journal of Molecular Sciences. 2023; 24(17): 13288. doi: 10.3390/ijms241713288
8. Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin-resistant states. Clinica Chimica Acta. 2006; 368(1-2): 1-19. doi: 10.1016/j.cca.2005.12.026
9. Brenta G. Why can insulin resistance be a natural consequence of thyroid dysfunction? Journal of Thyroid Research. 2011; 2011: 152850. doi: 10.4061/2011/152850
10. Thongtang N, Sukmawan R, Llanes EJB, Lee ZV. Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices. Preventive Medicine Reports. 2022; 27: 101819. doi: 10.1016/ j.pmedr.2022.101819
11. Voskamp PWM, van Diepen M, Dekker FW, Hoogeveen EK. Dyslipidemia and risk of renal replacement therapy or death in incident pre-dialysis patients. Scientific Reports. 2018; 8(1): 3130. doi: 10.1038/s41598-018-20907-y
12. Alshamiri M, Ghanaim MMA, Barter P, Chang KC, Li JJ, Matawaran BJ, et al. Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East. International Journal of General Medicine. 2018; 11: 313-322. doi: 10.2147/IJGM.S160555
13. Lipid disorders. https://knowledge.manus.amboss.com/us/knowledge/Lipid_disorders#Zcda3 cd26eb 96cd54003c160020d7eb9b. 2026.
14. Joshi SR, Anjana RM, Deepa M, Pradeepa R, Bhansali A, Dhandania VK, et al. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. PLoS One. 2014; 9(5): e96808. doi: 10.1371/journal.pone. 0096808
15. Gu D, Wang D, Zhu Q, Luo L, Zhang T. Prevalence of dyslipidemia and associated factors in sedentary occupational population from Shanghai: A cross-sectional study. Archives of Public Health. 2024; 82(1): 21. doi: 10.1186/s13690-024-01245-0
16. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25): 3143-3421
17. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285(19): 2486-2497. doi: 10.1001/jama.285.19.2486
18. Ali N, Kathak RR, Fariha KA, Taher A, Islam F. Prevalence of dyslipidemia and its associated factors among university academic staff and students in Bangladesh. BMC Cardiovascular Disorders. 2023; 23(1): 366. doi: 10.1186/s12872-023-03399-1
19. Ko S, Kim H. Menopause-associated lipid metabolic disorders and foods beneficial for postmenopausal women. Nutrients. 2020; 12(1): 202. doi: 10.3390/nu12010202
20. Kolovou G, Bilianou HG. Influence of aging and menopause on lipids and lipoproteins in women. Angiology. 2008; 59(Suppl 2): 1S-10S. doi: 10.1177/0003319708319645
21. Trapani L, Pallottini V. Age-related hypercholesterolemia and HMG-CoA reductase dysregulation: Sex does matter (A gender perspective). Current Gerontology and Geriatrics Research. 2010; 2010: 420139. doi: 10.1155/ 2010/420139
22. Huang C, Zhang W, Tang W, Liu Y, Liu JX, Xu R, et al. Prevalence and related factors of dyslipidemia among urban adults aged 35 to 79 years in Southwestern China. Scientific Reports. 2021; 11(1): 96864. doi: 10.1038/ s41598-021-96864-w
23. Liu HH, Li JJ. Aging and dyslipidemia: A review of potential mechanisms. Ageing Research Reviews. 2015; 19: 43-52. doi: 10.1016/j.arr.2014.12.001
24. Hawaldar R, Sodani S, Sodani V, Sodani R. Study of the pattern of dyslipidemia in urban population of central Madhya Pradesh. The Journal of Community Health Management. 2019; 6(4): 127-135. doi: 10.18231/j.jchm. 2019.026
25. Abujbara M, Batieha A, Khader Y, Jaddou H, El-Khateeb M, Ajlouni K. The prevalence of dyslipidemia among Jordanians. Journal of Lipids. 2018; 2018: 6298739. doi: 10.1155/2018/6298739
26. MacDonald T. Prevalence of High Cholesterol Among the Adult U.S. Population: NHANES 2013-2018. Current Developments in Nutrition. 2022; 6(Suppl 1): 925. doi: 10.1093/cdn/nzac067.045
27. Metelskaya VA, Shalnova SA, Yarovaya EB, Kutsenko VA, Boytsov SA, Shlyakhto EV, et al. Lipoprotein profile in populations from regions of the russian federation: ESSE-RF Study. International Journal of Environmental Research and Public Health. 2022; 19(2): 931. doi: 10.3390/ijerph19020931
28. Alsheikh-Ali AA, Omar MI, Raal FJ, Rashed W, Hamoui O, Kane A, et al. Cardiovascular risk factor burden in Africa and the Middle East: The Africa Middle East Cardiovascular Epidemiological (ACE) study. PLoS One. 2014; 9(8): e102830. doi: 10.1371/journal.pone.0102830
29. Tóth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003-2006. Journal of Clinical Lipidology. 2012; 6(4): 325-330. doi: 10.1016/j. jacl.2012.05.002
30. Okpara IC, Adediran OS. Dyslipidemia and its relationship with different anthropometric measures in Nigerian adults. IOSR Journal of Dental and Medical Sciences. 2013; 9(3): 7-12. doi: 10.9790/0853-0930712
31. Gebreegziabiher G, Belachew T, Mehari K, Tamiru D. Prevalence of dyslipidemia and associated risk factors among adult residents of Mekelle City, Northern Ethiopia. PLoS One. 2021; 16(2): e0243103. doi: 10.1371/ journal.pone.0243103
32. Tabatabaei-Malazy O, Qorbani M, Samavat T, Sharifi F, Larijani B, Fakhrzadeh H. Prevalence of dyslipidemia in Iran: A systematic review and meta-analysis study. International Journal of Preventive Medicine. 2014; 5(4): 373-393. doi: Nil.
33. Mahmoud I, Sulaiman N. Dyslipidaemia prevalence and associated risk factors in the United Arab Emirates: a population-based study. British Medical Journal Open. 2019; 9(11): e031969. doi: 10.1136/bmjopen-2019-031969
34. Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine. 2008; 34(1-3): 36-51. doi: 10.1007/s12020-008-9100-z
35. Mula-Abed WA, Chilmeran SK. Prevalence of dyslipidemia in the Iraqi adult population. Saudi Medical Journal. 2007; 28(12): 1868-1874. doi: Nil.
36. Micah FB, Nkum BC. Lipid disorders in hospital attendants in Kumasi, Ghana. Ghana Medical Journal. 2012; 46(1): 14-21. doi: Nil.
37. Miccoli R, Bianchi C, Odoguardi L, Penno G, Caricato F, Giovannitti MG, et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutrition, Metabolism, and Cardiovascular Diseases. 2005; 15(4): 250-254. doi: 10.1016/j.numecd.2004.09.002
38. Al-Lawati JA, Mohammed AJ, Al-Hinai HQ, Jousilahti P. Prevalence of the metabolic syndrome among Omani adults. Diabetes Care. 2003; 26(6): 1781-1785. doi: 10.2337/diacare.26.6.1781
39. Costa J, Borges M, Oliveira E, Gouveia M, Carneiro AV. Incidence and prevalence of hypercholesterolemia in Portugal: a systematic review. Part III. Portuguese Journal of Cardiology. 2003; 22(6): 829-836. doi: Nil.
40. Hadj-Taieb S, Elasmi M, Hammami MB, Marrakchi R, Amani K, Omar S, et al. Dyslipidemia in the greater Tunis population: Prevalence and determinants. Clinical Laboratory. 2012; 58(7-8): 763-770. doi: Nil.
41. Rampal S, Mahadeva S, Guallar E, Bulgiba A, Mohamed R, Rahmat R, et al. Ethnic differences in the prevalence of metabolic syndrome: results from a multi-ethnic population-based survey in Malaysia. PLoS One. 2012; 7(9): e46365. doi: 10.1371/journal.pone.0046365
42. Al-Nozha MM, Arafah MR, Al-Maatouq MA, Khalil MZ, Khan NB, Al-Marzouki K, et al. Hyperlipidemia in Saudi Arabia. Saudi Medical Journal. 2008; 29(2): 282-287. doi: Nil.
43. Reiger S, Jardim TV, Abrahams-Gessel S, Crowther NJ, Wade A, Gomez-Olive FX, et al. Awareness, treatment, and control of dyslipidemia in rural South Africa: The HAALSI (Health and Aging in Africa: A longitudinal study of an INDEPTH community in South Africa) study. PLoS One. 2017; 12(10): e0187347. doi: 10.1371/ journal.pone. 0187347
44. Doupa D, Mbengue AS, Diallo FA, Jobe M, Ndiaye A, Kane A, et al. Lipid profile frequency and the prevalence of dyslipidaemia from biochemical tests at Saint Louis University Hospital in Senegal. The Pan African Medical Journal. 2014; 17: 75. doi: 10.11604/pamj.2014.17.75.3577
45. NHS England, Health Survey for England, 2021, part 2, adults' health: cholesterol. Available from: https:// digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2021-part-2/adult-health -cholesterol.
46. Streja D, Streja E. Management of Dyslipidemia in the Elderly. 2020. Available from: https://www.endotext. org/wp-content/uploads/pdfs/management-of-dyslipidemia-in-the-elderly.pdf.
47. Kosmas CE, Pantou D, Sourlas A, Papakonstantinou EJ, Echavarria Uceta R, Guzman E. New and emerging lipid-modifying drugs to lower LDL cholesterol. Drugs in Context. 2021; 10: 2021-8-3. doi: 10.7573/dic.2021-8-3
48. Agnello F, Ingala S, Laterra G, Scalia L, Barbanti M. Novel and emerging LDL-C lowering strategies: A new era of dyslipidemia management. Journal of Clinical Medicine. 2024; 13(5): 1251. doi: 10.3390/jcm13051251
49. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal. 2020; 41(1): 111-188. doi: 10.1093/eurheartj/ehz455
50. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomized trials. The Lancet. 2010; 376(9753): 1670-1681. doi: 10.1016/S0140-6736(10) 61350-5
51. Uthirapathy S. Emerging lipid-lowering therapies: A comprehensive review of novel agents targeting hyperlipidemia. Journal of Angiotherapy. 2024; 8(10): 9920. doi: 10.25163/angiotherapy.8109920
52. Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10th Ed., New York: McGraw-Hill; 2001. ISBN: 978-1-25-985-8474-9.
53. Bellosta S, Paoletti R, Corsini A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation. 2004; 109(23 Suppl 1): III50-III57. doi: 10.1161/01.CIR.0000131519.15067.1f
54. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: A network meta-analysis of 170,255 patients from 76 randomized trials. QJM: An International Journal of Medicine. 2011; 104(2): 109-124. doi: 10.1093/qjmed/hcq165
55. Zhao H, Wang Y, Li Y, Cheng R, Chen W. Research advances in current drugs targeting hyperlipidemia (Review). Molecular Medicine Reports. 2025; 32(4): 258. doi: 10.3892/mmr.2025.13623
56. Feingold KR. Maximizing the benefits of cholesterol-lowering drugs. Current Opinion in Lipidology. 2019; 30(5): 388-394. doi: 10.1097/MOL.0000000000000631
57. Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocrine Reviews. 2022; 43(4): 611-653. doi: 10.1210/endrev/bnab037
58. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. The New England Journal of Medicine. 2015; 372(25): 2387-2397. doi: 10.1056/NEJMoa1410489
59. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal. 2010; 160(5): 785-794.e10. doi: 10.1016/j.ahj.2010.08.012
60. Jain P. Traditional and novel non-statin lipid-lowering drugs. Indian Heart Journal. 2024; 76(Suppl 1): S38-S43. doi: 10.1016/j.ihj.2023.11.003
61. Diabetes Canada Clinical Practice Guidelines Expert Committee, Mancini GBJ, Hegele RA, Leiter LA. Dyslipidemia. Canadian Journal of Diabetes. 2018; 42(Suppl 1): S178-S185. doi: 10.1016/j.jcjd.2017.10.019
62. Fruchart JC, Hermans MP, Fruchart-Najib J, Kodama T. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) in the metabolic syndrome: Is pemafibrate light at the end of the tunnel? Current Atherosclerosis Reports. 2021; 23(1): 3. doi:10.1007/s11883-020-00897-x
63. Carlson LA. Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. Journal of Internal Medicine. 2005; 258(2): 94-114. doi: 10.1111/j.1365-2796.2005.01528.x
64. Taher ZA, Taher AA, Radi S. An update on dyslipidemia management and medications: A review. Cureus. 2024; 16(3): e56255. doi: 10.7759/cureus.56255
65. Crouse JR 3rd. Hypertriglyceridemia: A contraindication to the use of bile acid binding resins. The American Journal of Medicine. 1987; 83(2): 243-248. doi: 10.1016/0002-9343(87)90692-9
66. Liu QK. Triglyceride-lowering and anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids for atherosclerotic cardiovascular risk reduction. Journal of Clinical Lipidology. 2021; 15(4): 556-568. doi: 10.1016 /j.jacl.2021.05.007
67. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. The New England Journal of Medicine. 2019; 380(1): 11-22. doi: 10.1056/NEJMoa1812792
68. Khan SU, Lone AN, Khan MS, Virani SS, Blumenthal RS, Nasir K, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. E Clinical Medicine. 2021; 38: 100997. doi: 10.1016/j.eclinm.2021.100997
69. Guo S, Xia XD, Gu HM, Zhang DW. Proprotein convertase subtilisin/kexin-type 9 and lipid metabolism. Advances in Experimental Medicine and Biology. 2020; 1276: 137-156. doi: 10.1007/978-981-15-6082-8_9
70. Rakipovski G, Hovingh GK, Nyberg M. Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin? Current Opinion in Lipidology. 2020; 31(6): 340-346. doi: 10.1097/MOL.0000000000000718
71. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. The New England Journal of Medicine. 2017; 376(18): 1713-1722. doi: 10.1056/NEJMoa1615664
72. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. The New England Journal of Medicine. 2018; 379(22): 2097-2107. doi: 10.1056/ NEJMoa1801174
73. Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. The New England Journal of Medicine. 2017; 376(1): 41-51. doi: 10.1056/ NEJMoa1609243
74. Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): Results from the 4-year open-label extension of the ORION-1 trial. The Lancet Diabetes and Endocrinology. 2023; 11(2): 109-119. doi: 10.1016/S2213-8587(22)00353-9
75. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. The New England Journal of Medicine. 2019; 380(11): 1022-1032. doi: 10.1056/ NEJMoa1803917
76. Burke AC, Telford DE, Huff MW. Bempedoic acid: Effects on lipoprotein metabolism and atherosclerosis. Current Opinion in Lipidology. 2019; 30(1): 1-9. doi: 10.1097/MOL.0000000000000565
77. Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nature Communications. 2016; 7: 13457. doi: 10.1038/ncomms13457
78. Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: The CLEAR wisdom randomized clinical trial. JAMA. 2019; 322(18): 1780-1788. doi: 10.1001/jama.2019.16585
79. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. The New England Journal of Medicine. 2023; 388(15): 1353-1364. doi: 10.1056/NEJMoa2215024
80. Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. European Journal of Preventive Cardiology. 2020; 27(6): 593-603. doi: 10.1177/ 2047487319864671
81. Laufs U, Ballantyne CM, Banach M, Bays H, Catapano AL, Duell PB, et al. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. Journal of Clinical Lipidology. 2022; 16(3): 286-297. doi: 10.1016/j.jacl.2022.03.001
82. Hamayal M, Shahid W, Akhtar CH, Shekiba F, Iftikhar I, Tahir MD, et al. Risk of cardiovascular outcomes with bempedoic acid in high-risk statin intolerant patients: a systematic review and meta-analysis. Future Cardiology. 2024; 20(11-12): 639-650. doi: 10.1080/14796678.2024.2388478
83. Tikka A, Jauhiainen M. The role of ANGPTL3 in controlling lipoprotein metabolism. Endocrine. 2016; 52(2): 187-193. doi: 10.1007/s12020-015-0838-9
84. Banerjee P, Chan KC, Tarabocchia M, Benito-Vicente A, Alves AC, Uribe KB, et al. Functional analysis of LDLR (low-density lipoprotein receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity. Arteriosclerosis, Thrombosis, and Vascular Biology. 2019; 39(11): 2248-2260. doi: 10.1161/ATVBAHA.119.313051
85. Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. The New England Journal of Medicine. 2020; 383(8): 711-720. doi: 10.1056/ NEJMoa2004215
86. Spagnuolo CM, Hegele RA. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors. Expert Opinion on Pharmacotherapy. 2023; 24(9): 1013-1020. doi: 10.1080/14656566.2023.2206015
87. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. The New England Journal of Medicine. 2020; 382(3): 244-255. doi: 10.1056/NEJMoa1905239
88. O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. The New England Journal of Medicine. 2022; 387(20): 1855-1864. doi: 10.1056/NEJMoa2211023
89. Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, et al. Zerlasiran-A small-interfering RNA targeting lipoprotein(a): A phase 2 randomized clinical trial. JAMA. 2024; 332(23): 1992-2002. doi: 10.1001/ jama.2024.21957
90. VERVE-101: CRISPR-based gene editing therapy shows promise in reducing LDL-C and PCSK9 levels in patients with HeFH-American College of Cardiology. Available online: https://www.acc.org/Latest-in-Cardiology/Articles/2023/11/08/20/14/sun-445pm-heart1-aha-2023

Citation :

Omran EA, et al. The burden of dyslipidaemia in an urban Libyan population: Epidemiological assessment and a review of modern therapy. Mediterr J Pharm Pharm Sci. 2026; 6(3): 50-64. [Article number: 261]. https://doi.org/10.5281/zenodo.21833847